Pharmacovigilance, traceability and building trust in biosimilar medicines

21 December 2017

The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Today, organisations representing the life science industry in the EU […]

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

29 November 2017

The European Commission launched today additional translations of the Q&A […]

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

The associations representing the European and British life science industry […]

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Medicines for Europe is very glad to see the Council […]

Manufacturing cost transparency could combat pricing criticism, says expert

2 November 2017

Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs

18 October 2017

On Thursday 12 October, the Directorate-general for Internal Market, Industry, […]

Medicines for Europe announces new President, launches Access to Medicines campaign

10 October 2017

The newly elected President of Medicines for Europe – Marc-Alexander Mahl – […]

European report calms common concerns

15 September 2017

2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments

12 September 2017

Biosimilar medicines are transforming treatment by enabling better access to […]